Literature DB >> 31877340

Drug repurposing for cancer therapy, easier said than done.

Aurora Gonzalez-Fierro1, Alfonso Dueñas-González2.   

Abstract

Drug repurposing for cancer therapy is currently a hot topic of research. Theoretically, in contrast to the known hurdles of developing new molecular entities, the approach of repurposing has several advantages. Mostly, it is said that it is faster, safer, easier, and cheaper. In the real world, however, there are only three repurposed drugs so far, that are listed in widely recognized cancer guidelines, but a large number of them are being studied. Among the many barriers to repurposing cancer drugs, economical-driven are the most important that difficult the clinical development of them. In this review, we provide an overview of the current status of drug repurposing for cancer therapy and the barriers that need to be overcome to realize the benefit of this approach. It means to have repositioned drugs for cancer therapy accepted as standard therapy for cancer indications at low cost.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cancer; Cancer biology; Cancer drug prices; Drug repurposing; Pharmacology

Mesh:

Substances:

Year:  2019        PMID: 31877340     DOI: 10.1016/j.semcancer.2019.12.012

Source DB:  PubMed          Journal:  Semin Cancer Biol        ISSN: 1044-579X            Impact factor:   15.707


  6 in total

1.  Bruceantin targets HSP90 to overcome resistance to hormone therapy in castration-resistant prostate cancer.

Authors:  Sue Jin Moon; Byong Chang Jeong; Hwa Jin Kim; Joung Eun Lim; Hye-Jeong Kim; Ghee Young Kwon; Joshua A Jackman; Jeong Hoon Kim
Journal:  Theranostics       Date:  2021-01-01       Impact factor: 11.556

2.  Sertaconazole provokes proapoptotic autophagy via stabilizing TRADD in nonsmall cell lung cancer cells.

Authors:  Wenhui Zhang; Li Zhou; Siyuan Qin; Jingwen Jiang; Zhao Huang; Zhe Zhang; Xiyu Zhang; Zheng Shi; Jie Lin
Journal:  MedComm (2020)       Date:  2021-12-16

Review 3.  Targeting Reactive Oxygen Species Capacity of Tumor Cells with Repurposed Drug as an Anticancer Therapy.

Authors:  Jiabing Wang; Dongsheng Sun; Lili Huang; Shijian Wang; Yong Jin
Journal:  Oxid Med Cell Longev       Date:  2021-09-07       Impact factor: 6.543

Review 4.  Application of Mesoporous Silica Nanoparticles in Cancer Therapy and Delivery of Repurposed Anthelmintics for Cancer Therapy.

Authors:  Maedeh Koohi Moftakhari Esfahani; Seyed Ebrahim Alavi; Peter J Cabot; Nazrul Islam; Emad L Izake
Journal:  Pharmaceutics       Date:  2022-07-29       Impact factor: 6.525

Review 5.  Drug repurposing in cancer neuroscience: From the viewpoint of the autophagy-mediated innervated niche.

Authors:  Jiayan Shi; Jia Xu; Yang Li; Bowen Li; Hui Ming; Edouard C Nice; Canhua Huang; Qifu Li; Chuang Wang
Journal:  Front Pharmacol       Date:  2022-08-29       Impact factor: 5.988

Review 6.  Mastoparans: A Group of Multifunctional α-Helical Peptides With Promising Therapeutic Properties.

Authors:  Carlos José Correia de Santana; Osmindo Rodrigues Pires Júnior; Wagner Fontes; Mário Sérgio Palma; Mariana S Castro
Journal:  Front Mol Biosci       Date:  2022-06-24
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.